Quick Answer
BioCardia, Inc. reported Research And Development Expense of $4.96 million for the year ending 2025.
- BioCardia, Inc. showed an increase of +13.1% in Research And Development Expense from 2024 to 2025.
- This data is from BioCardia, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $441.0 thousand | Q2 2016: $497.0 thousand | Q3 2016: $684.0 thousand | Q1 2017: $1.03 million | Q2 2017: $1.30 million | Q3 2017: $1.70 million | Q1 2018: $1.96 million | Q2 2018: $2.03 million | Q3 2018: $2.26 million | Q1 2019: $2.17 million | Q2 2019: $2.22 million | Q3 2019: $2.01 million | Q1 2020: $2.79 million | Q2 2020: $2.22 million | Q3 2020: $2.47 million | Q1 2021: $1.84 million | Q2 2021: $2.36 million | Q3 2021: $2.24 million | Q1 2022: $2.19 million | Q2 2022: $2.30 million | Q3 2022: $2.14 million | Q1 2023: $2.38 million | Q2 2023: $2.31 million | Q3 2023: $1.87 million | Q1 2024: $1.24 million | Q2 2024: $800.0 thousand | Q3 2024: $931.0 thousand | Q1 2025: $1.53 million | Q2 2025: $1.37 million | Q3 2025: $936.0 thousand.
- Over the full 11 years of available data (2015 to 2025), BioCardia, Inc.'s Research And Development Expense has grown by 226.9%.
- Historical annual values: Fiscal year 2025: $4.96 million | Fiscal year 2024: $4.39 million | Fiscal year 2023: $7.73 million | Fiscal year 2022: $8.83 million | Fiscal year 2021: $8.56 million | Fiscal year 2020: $9.81 million | Fiscal year 2019: $8.56 million | Fiscal year 2018: $8.45 million | Fiscal year 2017: $5.80 million | Fiscal year 2016: $3.33 million | Fiscal year 2015: $1.52 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: